Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 4/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 3/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | GPR6 | P46095 | 3/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8037163 | 0.88 | GSK3B (0.47) | GSK3BBTKKITHCRTR1GPR6 | |
| Hydrochloric Acid SCHEMBL4281336 | 0.88 | GSK3B (0.46) | GSK3BBTKKITHCRTR1GPR6 | |
| SCHEMBL3166278 | 0.85 | PDE2A (0.33) | ACKR3PDE2AKITADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL4292984 | 0.76 | ADORA2A (0.34) | GSK3BBTKNTRK1ADORA2AADORA1 | |
| SCHEMBL2246653 | 0.74 | GSK3B (0.34) | GSK3BPIK3CD | |
| SCHEMBL2245172 | 0.73 | KDM4E (0.39) | — | |
| SCHEMBL7956666 | 0.72 | GSK3B (0.47) | GSK3BBTKHCRTR1GPR6 | |
| SCHEMBL1962713 | 0.72 | BMPR1B (0.34) | ACKR3BTKADORA2A | |
| Hydrochloric Acid SCHEMBL2247528 | 0.72 | GSK3B (0.46) | GSK3BBTKHCRTR1GPR6 | |
| SCHEMBL4287388 | 0.71 | GSK3B (0.51) | GSK3BBTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | GSK3B 2707/4885ACKR3 1329/4885BTK 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.